Filter
289
Text search:
Unitaid
Featured
39
55
Language
Document type
114
67
44
24
20
10
4
2
2
1
Countries / Regions
28
7
6
4
4
3
3
3
3
3
3
3
2
2
2
2
2
2
2
1
1
1
1
1
1
1
1
1
1
1
1
1
1
1
1
1
Authors & Publishers
Publication Years
Category
52
42
15
12
7
3
1
Toolboxes
65
54
28
24
16
13
9
6
4
3
2
2
1
1
This implementation tool describes the recommended approaches for routine monitoring of toxicity integrated with the national monitoring and evaluation system and targeted approaches to monitoring toxicity to enable enhanced monitoring and reporting of treatment-limiting toxicity to support country
...
Joint United Nations Programme on HIV/AIDS (UNAIDS).
Le rapport 2016 fait état de la situation du VIH dans notre pays en rappelant les enjeux et défis en rapport avec le contexte international. Il renseigne également sur la situation du VIH, les financements et programmes mis en œuvre et les résultats obtenus.
Le rapport 2016 fait état de la situation du VIH dans notre pays en rappelant les enjeux et défis en rapport avec le contexte international. Il renseigne également sur la situation du VIH, les financements et programmes mis en œuvre et les résultats obtenus.
Antimicrobial resistance is a global crisis that threatens a century of progress in health and achievement of the Sustainable Development Goals. There is no time to wait. Unless the world acts urgently, antimicrobial resistance will have disastrous impact within a generation.
This FY 2019 Malaria Operational Plan presents a detailed implementation plan for Burkina Faso, based on the strategies of PMI and the National Malaria Control Program (NMCP). It was developed in consultation with the NMCP and with the participation of national and international partners involved in
...
On 15–16 December 2020, WHO and the Medicines for Malaria Venture co-convened a technical consultation to consider the preferred product characteristics (PPCs) for drugs used in malaria chemoprevention. The main goal of the technical consultation was to agree on the most important PPCs for drugs t
...
WHO published the first COVID-19 Strategic Response and Preparedness Plan (SPRP) on 3 February, 2020. This report highlights the main points of progress that were made up to 30 June 2020 under the three objectives outlined in the SPRP: scaling up international coordination and support; scaling up co
...
The two-year impact report for the Access to COVID-19 Tools (ACT) Accelerator details impact, case studies and timelines of key milestones for the Diagnostics, Therapeutics and Vaccines pillars, as well as the Health Systems and Response Connector.
The COVID-19 pandemic has exposed the inadequacy of investments in public health, the persistence of profound economic and social inequalities and the fragility of many key global systems and approaches.
The Global Strategy for Tuberculosis Research and Innovation will support the efforts of governments and other stakeholders to accelerate TB research and innovation, and improve equitable access to the benefits of research.
Availabl in Arabic, Chinese, English, French, Spanish and Russian
Orientations provisoires, 16 novembre 2020
Ce document d’orientation a été conçu à l’intention des autorités nationales chargées de gérer le déploiement, la mise en œuvre et le suivi des vaccins contre la COVID-19, ainsi que des partenaires qui fourniss
...
WHO‘s Global Strategy to Accelerate the Elimination of Cervical Cancer, launched today, outlines three key steps: vaccination, screening and treatment. Successful implementation of all three could reduce more than 40% of new cases of the disease and 5 million related deaths by 2050.
Despite being a curable and preventable disease, tuberculosis (TB) remains as one of the major challenges for health systems, globally. Every year, TB affects more than 10 million people and kills more than 1.4 million people. WHO’s Digital Health for the End TB Strategy – an Agenda for Action o
...
Tuberculosis cases, TB deaths
1 February 2021 to 31 January 2022
These guidelines provide new and updated recommendations on the use of point-of-care testing in children under 18 months of age and point-of-care tests to monitor treatment in people living with HIV; the treatment monitoring algorithm; and timing of antiretroviral therapy (ART) among people living w
...
